Effect of Bumetanide on brain function in autism spectrum disorder
Phase 2
- Conditions
- Autism Spectrum Disorder.Autistic disorderF84.0
- Registration Number
- IRCT20180901040915N1
- Lead Sponsor
- Institute for Cognitive Science Studies
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Diagnosed as a autism spectrum disorder, level 1 (needing support) according to DSM-V
IQ above 70
Exclusion Criteria
Karyotype abnormalities or neurological records including epilepsy and febrile seizures
A history of allergy to sulfonamides
liver or kidney dysfunction, heart disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of the latency and amplitude of brain signals faced with emotional faces. Timepoint: Before the intervention and one week after the intervention. Method of measurement: Brain Event Related Potentials Recording.;Attention to eyes. Timepoint: Before the intervention and one week after the intervention. Method of measurement: Eye Track Recording.
- Secondary Outcome Measures
Name Time Method Severity of the symptoms. Timepoint: One week before the intervention, sixth week of the intervention, and one week after the intervention. Method of measurement: Interview with the parents and completing the Childhood Autism Rating Scale questionnaire.;Evaluation of the communication and social relationships. Timepoint: One week before the intervention, sixth week of the intervention, and one week after the intervention. Method of measurement: Social Responsiveness Scale questionnaire completion.